Afyren
AFYREN meets a growing need among businesses and industries to reduce the use of petroleum-based products in their production lines. It does this by producing biomolecules derived from non-food biomass, largely used in the sectors of cosmetics, flavors and fragrances, feed and food, and fine chemicals. This production of renewable carbon, within a circular economy, is achieved through worldwide patented fermentation technology resulting from 10 years of research. Afyren went public in October 2021 on the Euronext Growth market (ALAFY).
Sector
Industrial Biotech
Strategies
Industrial Biotech
Status
Active
Website
afyren.com
Related News
Afyren provides business update on its Afyren Neoxy plant
AFYREN is ramping up its efforts to create a new path for organic waste recovery
Production operations at AFYREN NEOXY plant make significant progress, with first lots delivered
AFYREN chooses Thailand for its second biobased organic acids plant, entering a partnership project with Mitr Phol, a global leader in the sugar industry
AFYREN adds new hires to support growth in France and expansion abroad
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.